Levetiracetam Tablet
Product Images NDC 71335-9757

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 71335-9757). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713359757)

Levetiracetam 500 mg oral tablet label displaying the NDC 71335-9757-1. It indicates repackaging by Bryant Ranch Prepack, Inc. in Burbank, CA, and manufacturing by Zhejiang Jingxin Pharmaceutical Co., Ltd. The label also notes a quantity of 90 tablets and includes storage and safety instructions.*

FDA Label Image

Structure Formula (Levetiracetam Tablets 1)

Chemical structure of levetiracetam showing its molecular composition and bonding arrangement as typically represented in pharmaceutical labeling.*

FDA Label Image

Figure 1 (Levetiracetam Tablets 2)

A bar chart showing the percentage of patients for three groups: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The y-axis represents the percentage of patients, and the x-axis denotes the treatment groups with sample sizes in parentheses.*

FDA Label Image

Figure2 (Levetiracetam Tablets 3)

A bar chart comparing the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Each bar is labeled with the respective percentage and sample size (N). The y-axis shows percentage of patients, and the x-axis lists the treatment groups.*

FDA Label Image

Figure3 (Levetiracetam Tablets 4)

A bar chart comparing the percentage of patients in two groups: Placebo (14.4%) and Levetiracetam 3000 mg/day (39.4%). The chart displays patient response rates with the x-axis labeling the treatment groups and the y-axis showing the percentage of patients ranging from 0% to 45%.*

FDA Label Image

Figure4 (Levetiracetam Tablets 5)

A bar graph comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The Placebo group shows approximately 19.6% of patients, while the Levetiracetam group shows approximately 44.6%. The graph includes an asterisk above the Levetiracetam bar.*

FDA Label Image

Figure5 (Levetiracetam Tablets 6)

A bar chart comparing the percentage of patients between placebo (N=51) and Levetiracetam (N=58) groups, showing higher patient percentage for Levetiracetam at 43.1% versus placebo at 19.6%. The Y-axis represents the percentage of patients.*

FDA Label Image

Figure6 (Levetiracetam Tablets 7)

A bar graph comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The y-axis represents the percentage of patients from 0% to 100%. The Placebo group shows approximately 45.2%, while the Levetiracetam group shows approximately 72.2%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.